Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.
Checkpoint immunotherapy
Immunosuppressive therapy
Myocarditis
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
09 Aug 2021
09 Aug 2021
Historique:
received:
05
03
2021
accepted:
16
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitor (ICI) induced myocarditis is a rare, severe, and often fatal adverse event. Evidence to guide appropriate immunosuppressive therapy is scarce. We present a case of ICI-induced myocarditis and a review of ICI-induced myocarditis cases to determine the most effective immunosuppressive therapeutic strategy for ICI-induced myocarditis. A systematic search of PubMed was carried out for treatment of ICI-induced myocarditis. Reference lists from identified articles were manually reviewed for additional cases. A total of 87 cases with ICI-induced myocarditis were identified. The majority were melanoma (n = 39), lung cancer (n = 19), renal cell cancer (n = 10), and thymoma cancer patients (n = 4). In 38 (44%) cases, patients received high-dose steroid treatment only. A total of 49 (56%) cases were treated with immunosuppressive agents other than steroid; a total of 13 different immunosuppressive agents were used, including alemtuzumab or abatacept. The median time to onset of symptoms after initiation of ICI was 16 days (range, 1-196 days); cardiotoxic symptoms developed after 2 cycles of ICI (range, 1-13 cycles). A total of 48% of cases were fatal. In cases treated with high-dose steroids only vs. cases treated with other immunosuppressive agents, fatality was 55% and 43% respectively. In 64 out of the 87 cases, tumor control was not described. In patients treated with high-dose steroids only, two patients had stable disease as best tumor response; in patients treated with other immunosuppressive agents, one complete response, one partial response and seven stable disease were noted as best tumor response. Overall, 11 studies were at low risk of bias (12.6%), 38 at moderate risk of bias (43.7%) and 38 at high risk of bias (43.7%). Immune checkpoint inhibitor induced myocarditis is a serious and often fatal adverse event. High-dose prednisolone, alemtuzumab or abatacept are all possible treatments options for ICI-induced myocarditis, whereas infliximab increases the risk of death from cardiovascular causes, and should be avoided. Further research is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitor (ICI) induced myocarditis is a rare, severe, and often fatal adverse event. Evidence to guide appropriate immunosuppressive therapy is scarce. We present a case of ICI-induced myocarditis and a review of ICI-induced myocarditis cases to determine the most effective immunosuppressive therapeutic strategy for ICI-induced myocarditis.
METHODS
METHODS
A systematic search of PubMed was carried out for treatment of ICI-induced myocarditis. Reference lists from identified articles were manually reviewed for additional cases.
RESULTS
RESULTS
A total of 87 cases with ICI-induced myocarditis were identified. The majority were melanoma (n = 39), lung cancer (n = 19), renal cell cancer (n = 10), and thymoma cancer patients (n = 4). In 38 (44%) cases, patients received high-dose steroid treatment only. A total of 49 (56%) cases were treated with immunosuppressive agents other than steroid; a total of 13 different immunosuppressive agents were used, including alemtuzumab or abatacept. The median time to onset of symptoms after initiation of ICI was 16 days (range, 1-196 days); cardiotoxic symptoms developed after 2 cycles of ICI (range, 1-13 cycles). A total of 48% of cases were fatal. In cases treated with high-dose steroids only vs. cases treated with other immunosuppressive agents, fatality was 55% and 43% respectively. In 64 out of the 87 cases, tumor control was not described. In patients treated with high-dose steroids only, two patients had stable disease as best tumor response; in patients treated with other immunosuppressive agents, one complete response, one partial response and seven stable disease were noted as best tumor response. Overall, 11 studies were at low risk of bias (12.6%), 38 at moderate risk of bias (43.7%) and 38 at high risk of bias (43.7%).
CONCLUSION
CONCLUSIONS
Immune checkpoint inhibitor induced myocarditis is a serious and often fatal adverse event. High-dose prednisolone, alemtuzumab or abatacept are all possible treatments options for ICI-induced myocarditis, whereas infliximab increases the risk of death from cardiovascular causes, and should be avoided. Further research is needed.
Identifiants
pubmed: 34365980
doi: 10.1186/s40959-021-00114-x
pii: 10.1186/s40959-021-00114-x
pmc: PMC8351114
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
27Informations de copyright
© 2021. The Author(s).
Références
Case Reports Immunol. 2019 Apr 30;2019:2539493
pubmed: 31183226
CJC Open. 2020 Nov 14;3(3):379-382
pubmed: 33778457
Cardiooncology. 2020 Sep 23;6:21
pubmed: 32983574
BMJ Case Rep. 2016 Jul 20;2016:
pubmed: 27440853
N Engl J Med. 2019 Jun 13;380(24):2377-2379
pubmed: 31189043
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Can J Cardiol. 2018 Jun;34(6):812.e1-812.e3
pubmed: 29801747
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Emerg Radiol. 2020 Aug;27(4):455-460
pubmed: 32130542
Semin Arthritis Rheum. 2019 Feb;48(4):736-740
pubmed: 29909921
Eur Heart J Case Rep. 2019 Jan 07;3(1):yty149
pubmed: 31020225
Cancer Sci. 2016 Jul;107(7):1055-8
pubmed: 27420474
Case Rep Oncol. 2019 Mar 21;12(1):260-276
pubmed: 31011325
Ann Intern Med. 2017 Nov 7;167(9):683-684
pubmed: 28869988
BMJ Case Rep. 2018 Jan 23;2018:
pubmed: 29367376
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33298621
Eur J Cancer. 2020 Jan;124:15-24
pubmed: 31707280
J Immunother Cancer. 2016 Aug 16;4:50
pubmed: 27532025
J Immunother Cancer. 2017 Nov 21;5(1):91
pubmed: 29157297
Eur J Heart Fail. 2017 May;19(5):682-685
pubmed: 28485549
Curr Oncol. 2019 Jun;26(3):e418-e421
pubmed: 31285688
J Immunother Cancer. 2015 Apr 21;3:11
pubmed: 25901283
J Thorac Oncol. 2020 Mar;15(3):e31-e32
pubmed: 32093854
Oncologist. 2020 Aug;25(8):e1242-e1245
pubmed: 32400023
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Oncologist. 2018 Aug;23(8):879-886
pubmed: 29802219
A A Pract. 2020 Apr;14(6):e01177
pubmed: 32132361
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
eNeurologicalSci. 2018 Nov 22;14:4-5
pubmed: 30533536
Urol Case Rep. 2020 Nov 28;34:101508
pubmed: 33318935
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Case Rep Oncol. 2017 Sep 6;10(3):809-812
pubmed: 29070994
Intern Med. 2018 Nov 1;57(21):3157-3162
pubmed: 29877257
Virchows Arch. 2019 Sep;475(3):279-301
pubmed: 31297595
Eur J Cancer. 2016 Jun;60:210-25
pubmed: 27084345
Melanoma Res. 2016 Jun;26(3):319-20
pubmed: 27110676
J Immunother Cancer. 2018 Dec 18;6(1):150
pubmed: 30563577
Cureus. 2019 Jun 10;11(6):e4869
pubmed: 31417814
N Engl J Med. 2019 Jun 13;380(24):2375-2376
pubmed: 31189042
Cardiovasc Pathol. 2012 Jul-Aug;21(4):245-74
pubmed: 22137237
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Can J Cardiol. 2017 Oct;33(10):1335.e13-1335.e15
pubmed: 28822650
Ann Intensive Care. 2020 Oct 16;10(1):143
pubmed: 33064239
J Oncol Pharm Pract. 2019 Jun;25(4):966-968
pubmed: 29444608
Ann Transl Med. 2020 Mar;8(5):250
pubmed: 32309397
HeartRhythm Case Rep. 2019 Jun 28;5(10):497-500
pubmed: 31700793
Br J Cancer. 2017 Sep 26;117(7):921-924
pubmed: 28797029
J Thorac Oncol. 2019 Feb;14(2):e36-e38
pubmed: 30391574
Gynecol Oncol Rep. 2018 Jun 01;25:74-77
pubmed: 29922709
BMJ Evid Based Med. 2018 Apr;23(2):60-63
pubmed: 29420178
Lung Cancer. 2016 Sep;99:117-9
pubmed: 27565924
Circulation. 2017 Nov 21;136(21):2085-2087
pubmed: 29158217
Eur J Cancer. 2018 Mar;91:171-173
pubmed: 29287903
Melanoma Res. 2017 Apr;27(2):155-158
pubmed: 27977496
Haematologica. 2018 Jul;103(7):e318-e321
pubmed: 29650641
J Immunother. 2018 Sep;41(7):332-335
pubmed: 29965858
Oncoimmunology. 2017 Aug 8;6(12):e1361097
pubmed: 29209563
Clin Toxicol (Phila). 2018 Jul;56(7):667-671
pubmed: 29126352
J Immunother. 2018 Jan;41(1):35-38
pubmed: 29077601
Lung Cancer. 2019 Sep;135:29-32
pubmed: 31446999
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
Curr Treat Options Cardiovasc Med. 2019 Jun 8;21(7):32
pubmed: 31175469
Can J Cardiol. 2018 Jan;34(1):92.e1-92.e3
pubmed: 29275889
N Engl J Med. 2019 Sep 26;381(13):1268-1277
pubmed: 31553841
Cardiovasc Pathol. 2020 May - Jun;46:107202
pubmed: 32062109
J Immunother. 2019 Oct;42(8):313-317
pubmed: 31206394
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Ann Oncol. 2020 Sep;31(9):1273-1275
pubmed: 32425357
Cardiovasc Pathol. 2020 Jul - Aug;47:107211
pubmed: 32268262
Circ Heart Fail. 2016 Oct;9(10):
pubmed: 27650418
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497